Table 5. Summary of treatment outcomes after chemotherapy in patients with POALs.

Studies	Patient no.	Stage	Histology types	Regimens	Treatment response	Survival
Ben Simon, et al. [13]	33	IE	MALT lymphoma	Chlorambucil	26 (79%):CR 7 (21%):PR
Song, et al. [14]	21	I-IIE	MALT lymphoma	CVP	16 (76%):CR 5 (24%):PR	5-year PFS: 66%
Nückel, et al. [15]	2	IE	MALT lymphoma	Rituximab	1 (50%):CR 1 (50%):PR
Ferreri, et al. [16]	8	IE: 4, IV: 4	MALT lymphoma	Rituximab	3 (37.5%):CR 2 (25%):PR
Tuncer, et al. [17]	10	IE	MALT lymphoma: 9; FL: 1	Rituximab	5 (50%): CR 5 (50%): PR
Sokol, et al. [18]	2	IE	MALT lymphoma	Rituximab	1 (50%):CR 1 (50%):PR	5-year PFS: 100%
Annibal, et al. [27]	6	IE	MALT lymphoma	Rituximab	4 (67%):CR 2(33%):PR
Mino, et al. [28]	10	I-IIE	MALT lymphoma	Rituximab	10 (100%):CR
Rigacc, et al. [29]	9	IE: 8, IV: 1	MALT lymphoma: 8; FL:1	Rituximab+ chlorambucil	8 (89%):CR 1 (11%):PR
Paik, et al. [30]	9	I-IIE: 7 IVE: 2	MALT lymphoma	CVP, CHOP, R-CVP, R-CHOP	9 (100%):CR
Present study	20	I-IIE1	MALT lymphoma	Total: 20 Chlorambucil: 5 Rituximab-based: 12 CHOP: 3	15 (75%):CR 4 (80%):CR 10 (83%):CR 1 (33.3):CR	5-year EFS: 94.4% 5-year OS: 100%

Abbreviations: POALs, primary ocular adnexal lymphomas; MALT, mucosa-associated lymphoid tissue; FL, follicular lymphoma; DLBCL (MALT): diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma; CVP, cyclophosphamide, vincristine, and prednisolone; CHOP, cyclophosphamide, vincristine, doxorubicin, prednisolone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; CR, complete remission; PR, partial remission; PFS, progression-free survival.